Literature DB >> 12815749

Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder?

Tatiana Roman1, Marcelo Schmitz, Guilherme V Polanczyk, Mariana Eizirik, Luis A Rohde, Mara H Hutz.   

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) is a complex childhood-onset psychiatric disorder characterized by marked symptoms of inattention, hyperactivity, and impulsivity. The role of genetic factors in its etiology is strongly supported by family, adoption, and twin studies. Although most of the molecular studies have investigated the dopamine D4 receptor gene (DRD4) and the dopamine transporter gene (DAT1) genes in its etiology, pharmacological and brain imaging evidences seem to indicate that genes of the adrenergic system could also be attractive for association studies. We investigated a sample of 96 Brazilian ADHD children and adolescents and their parents for the ADRA2A MspI polymorphism. Although no association with either MspI allele was observed through the haplotype relative risk (HRR) analysis, effects of the ADRA2A gene on inattention and combined (inattention + hyperactivity/impulsivity) symptom scores were detected (U = 222.5, z = 2.19, P = 0.03; and U = 208.5, z = 2.32, P = 0.02, respectively). Our results suggest that the ADRA2A gene might have a small effect on ADHD susceptibility or that this gene might modulate the severity of the disorder. They are also consistent with the noradrenergic theories of ADHD, suggesting a role for the alpha2A adrenergic receptors in the disorder. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815749     DOI: 10.1002/ajmg.b.20018

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  30 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

2.  Candidate gene associations with withdrawn behavior.

Authors:  David H Rubin; Robert R Althoff; Erik A Ehli; Gareth E Davies; David C Rettew; Eileen T Crehan; John T Walkup; James J Hudziak
Journal:  J Child Psychol Psychiatry       Date:  2013-06-28       Impact factor: 8.982

3.  Sequence analysis of the ADRA2A coding region in children affected by attention deficit hyperactivity disorder.

Authors:  Taryn Castro; Heidi Eliana Mateus; Dora Janeth Fonseca; Diego Forero; Carlos Martín Restrepo; Claudia Talero; Alberto Vélez; Paul Laissue
Journal:  Neurol Sci       Date:  2013-11-01       Impact factor: 3.307

4.  The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.

Authors:  Amy F T Arnsten
Journal:  J Pediatr       Date:  2009-05-01       Impact factor: 4.406

Review 5.  Catecholamine influences on dorsolateral prefrontal cortical networks.

Authors:  Amy F T Arnsten
Journal:  Biol Psychiatry       Date:  2011-04-13       Impact factor: 13.382

6.  Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression.

Authors:  Kersten M Small; Kari M Brown; Carrie A Seman; Cheryl T Theiss; Stephen B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

7.  Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults.

Authors:  W Retz; M Rösler; C Kissling; S Wiemann; R Hünnerkopf; A Coogan; J Thome; C Freitag
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 8.  Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Authors:  Tanya E Froehlich; James J McGough; Mark A Stein
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

9.  Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type.

Authors:  T L da Silva; T G Pianca; T Roman; M H Hutz; S V Faraone; M Schmitz; L A Rohde
Journal:  J Neural Transm (Vienna)       Date:  2008-01-16       Impact factor: 3.575

Review 10.  The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.

Authors:  Mark A Stein; James J McGough
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.